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Abstract
Background: Experimental treatments pass through various stages of development. If a treatment passes
through early phase experiments, the investigators may want to assess it in a late phase randomised controlled
trial. An efficient way to do this is adding it as a new research arm to an ongoing trial. This allows to add the
new treatment while the existing arms continue. The familywise type I error rate (FWER) is often a key
quantity of interest in any multi-arm trial. We set out to clarify how it should be calculated when new arms are
added to a trial some time after it has started.
Methods: We show how the FWER, any-pair and all-pairs powers can be calculated when a new arm is added
to a platform trial. We extend the Dunnett probability and derive analytical formulae for the correlation
between the test statistics of the existing pairwise comparison and that of the newly added arm. We also verify
our analytical derivation via simulations.
Results: Our results indicate that the FWER depends on the shared control arm information (i.e. individuals in
continuous and binary outcomes and primary outcome events in time-to-event outcomes) from the common
control arm patients and the allocation ratio. The FWER is driven more by the number of pairwise
comparisons and the corresponding (pairwise) Type I error rates than by the timing of the addition of the new
arms. The FWER can be estimated using Sˇida´k’s correction if the correlation between the test statistics of
pairwise comparisons is less than 0.30.
Conclusions: The findings we present in this article can be used to design trials with pre-planned deferred
arms or to design new pairwise comparisons within an ongoing platform trial where control of the pairwise
error rate (PWER) or FWER (for a subset of pairwise comparisons) is required.
Keywords: platform trials; familywise type I error rate; intermediate outcomes; FWER; STAMPEDE trial;
survival time
1 Introduction
Many recent developments in clinical trials are aimed
at speeding up research by making better use of re-
sources. Phase III clinical trials can take several years
to complete in many disease areas, requiring consid-
erable resources. During this time, a new promising
treatment which needs to be tested may emerge. The
practical advantages of incorporating such a new ex-
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perimental arm into an existing trial protocol have
been clearly described in [1] [2] [3] [4], not least be-
cause it obviates the often lengthy process of initiating
a new trial and competing for patients. One trial using
this approach is the STAMPEDE trial [5] in men with
high-risk prostate cancer. STAMPEDE is a multi-arm
multi-stage (MAMS) platform trial that was initiated
with one common control arm and five experimental
arms assessed over four stages. Five new experimen-
tal arms have been added since its conception [1] -
see Section 2 for further details. This was done within
the paradigm of a ‘platform’ that has a single mas-
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ter protocol in which multiple treatments are evalu-
ated over time. It offers flexible features such as early
stopping of accrual to treatments for lack-of-benefit,
or adding new research treatments to be tested dur-
ing the course of a trial. There might also be scenarios
when at the design stage of a new trial another exper-
imental arm is planned to be added after the start of
the trial, i.e. a planned addition. An example of this
scenario is the RAMPART trial in renal cancer - see
Section 4. In some platform designs, however, the ad-
dition of the new experimental arm would be intended
but not specially planned at the start of the platform,
i.e. unplanned, and is opportunistic at a later stage.
The Type I error rate is one of the key quantities in
the design of any clinical trial. Two measures of Type
I error in a multi-arm trial are the pairwise (PWER)
and familywise (FWER) type I error rates. The PWER
is the probability of incorrectly rejecting the null hy-
pothesis for the primary outcome of a particular ex-
perimental arm at the end of the trial, regardless of
other experimental arms in the trial. The FWER is the
probability of incorrectly rejecting the null hypothesis
for the primary outcome for at least one of the ex-
perimental arms from a set of comparisons in a multi-
arm trial. It gives the Type I error rate for a set of
pairwise comparisons of the experimental arms with
the control arm. In trials with multiple experimen-
tal arms the maximum possible FWER often needs to
be calculated and known - see [6] for details. In some
multi-arm trials, this maximum value needs to be con-
trolled at a pre-defined level. This is called a strongly
controlled FWER as it covers all eventualities, i.e. all
possible hypotheses [7]. Dunnett [8] developed an an-
alytical formula to calculate the FWER in multi-arm
trials when all the pairwise comparisons of experimen-
tal arms against the control arm start and conclude at
the same time. However, it has been unclear how to
calculate the FWER when new experimental arms are
added during the course of a trial.
The purpose of this article is threefold. First, we
describe how the FWER, disjunctive (any-pair) and
conjucntive (all-pairs) powers - see Section 3 for their
definitions - can be calculated when a new experimen-
tal arm is added during the course of an existing trial
with continuous, binary and time-to-event outcomes.
Second, we describe how the FWER can be strongly
controlled at a prespecified level for a set of pairwise
comparisons in both planned (i.e. the added arm is
planned at the design stage) and unplanned (e.g. such
as platform designs) scenarios. Third, we explain how
the decision to control the PWER or the FWER in a
particular design involves a subtle balancing of both
practical and statistical considerations [9]. This ar-
ticle outlines these issues, and provides guidance on
whether to emphasise the PWER or the FWER in
different design scenarios when adding a new experi-
mental arm.
The structure of the article is as follows. In Sec-
tion 2, the design of the STAMPEDE platform trial
is presented. In Section 3, Methods, we explain how
the FWER, disjunctive and conjunctive powers are
computed when a new experimental arm is added to
an ongoing trial. In Section 4, Results, we present
the outcome of our simulations to verify our analyt-
ical derivation. We also show two applications in both
planned (i.e. RAMPART trial in renal cancer) and
platform design (i.e. STAMPEDE trial) settings. In
Section 5, based on our empirical investigations, we
propose strategies that can be applied to strongly con-
trol the FWER when adding new experimental arms
to an ongoing platform trial in scenarios where such a
control is required. Finally, Section 6 is a discussion.
2 An example: STAMPEDE trial
STAMPEDE [1] is a multi-arm multi-stage (MAMS)
platform trial for men with prostate cancer at high
risk of recurrence who are starting long-term andro-
gen deprivation therapy [1]. In a four-stage design, five
experimental arms with treatment approaches previ-
ously shown to be safe were compared with a control
arm regimen. In this trial, the primary analysis was
carried out at the end of stage 4, with overall survival
as the primary outcome. Stages 1 to 3 used an inter-
mediate outcome measure of failure-free survival. As a
result, the corresponding hypotheses at interim stages
played a subsidiary role - i.e. used for lack-of-benefit
analysis on an intermediate outcome, not for making
claims of efficacy. We, therefore, focus on the primary
hypotheses on overall survival at the final stage - as
outlined below.
Recruitment to the original design began late in 2005
and was completed early in 2013. The design param-
eters for the primary outcome at the final stage were
a (one-sided) significance level of 0.025, power of 0.90,
and the target hazard ratio of 0.75 on overall survival
which required 401 control arm deaths (i.e. events on
overall survival). An allocation ratio of A = 0.5 was
used for the original comparisons so that, over the
long-term, one patient was allocated to each experi-
mental arm for every two patients allocated to con-
trol. Because distinct hypotheses were being tested in
each of the five experimental arms, the emphasis in the
design for STAMPEDE was on the pairwise compar-
isons of each experimental arm against control, with
emphasis on the strong control of the PWER. Out of
the initial five experimental arms, only three of them
continued to recruit through to their final stage. Re-
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Figure 1: Schematic representation of the control and experimental arm timelines in the STAMPEDE trial.
Below section: the thick horizontal bars represent the accrual period, and the following solid lines represent the
follow-up period. Top section: the striped bars represent the period when the recruited control arm patients
overlap during this period between different pairwise comparisons. The colours of the stripes represent the
colours of each pairwise comparison. For example, the striped bar that is labelled as S(1, 2, 4; 6) represents the
period when the recruited control arm patients are shared between the original pairwise comparisons 1, 2, and
4 and the 6th newly added comparison during this period.
cruitment to the other two arms stopped at the second
interim look due to lack of sufficient activity.
Since November 2011, five new experimental arms
have been added to the original design. Figure 1
presents the timelines for different arms, including
three of those added later. [Figure 1 NEAR HERE].
Note that patients allocated to a new experimental
arm are only compared with patients randomised to
the control arm contemporaneously, and recruitment
to the new experimental arm(s) continue for as long
as is required. Therefore, the analysis and reporting of
the new comparisons will be later than for the original
comparisons. Figure 1 also shows the recruitment peri-
ods when the pairwise comparisons of the newly-added
experimental arms with the control overlap with each
other as well as with those of the original comparisons
- see the top section of Figure 1.
3 Methods
In this section, we first present the formulae for the cor-
relation of the two test statistics when one of the com-
parisons is added later in trials with continuous, binary
and survival outcomes. We then describe how Dun-
nett’s test can be extended to compute the FWER, as
well as conjunctive and disjunctive powers when a new
arm is added mid-course of a two arm trial.
3.1 Type I error rates when adding a new arm
In a two arm trial, the primary comparison is between
the control group (C) and the experimental treatment
(E). The parameter θ represents the difference in the
outcome measure between the two groups. In the no-
tation of this article, the control group is always iden-
tified with subscript 0. For continuous outcomes, θ
could be the difference in the means of the two groups
µ1 − µ0; for binary data difference in the proportions
p1 − p0; for survival data a log hazard ratio (logHR).
The efficient score statistic for θ (based on the avail-
able data and calculated under the null hypothesis that
θ = 0) is represented by S with V being the Fisher’s
(observed) information about θ contained in S. Con-
ditionally on the value of V , in large samples (which
is the underlying assumption throughout this article),
S follows the normal distribution with mean θV and
variance V , i.e. S ∼ N( θV, V ). In the survival case, S
and V are the logrank test statistic and its null vari-
ance, respectively.
In practice, the progress of a trial can be assessed in
terms of ‘information time’ t because it measures how
far through the trial we are [10]. In the case of continu-
ous and binary outcomes, t is defined as the total num-
ber of individuals accrued so far divided by the total
sample size. In survival outcomes, it is defined as the
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total number of events occurred so far divided by the
total number of events required by the planned end of
the trial [10]. In all cases t = 0 and t = 1 correspond to
the beginning and end of the trial, respectively. In con-
tinuous, binary and survival outcome data, S has inde-
pendent and normally distributed increment structure.
This means that at information times t1 , t2, ..., tj the
increments S(t
1
), S(t
2
)−S(t
1
), ..., S(t
j
)−S(tj−1) are
independently and normally distributed.
Furthermore, the Z test statistic can be expressed
in terms of the efficient score statistic S and Fisher’s
information as Z = S/
√
V . The Z test statistic is (ap-
proximately) normally distributed Z ∼ N( θ
√
V , 1)
and has the same independent increment property as
that of S. For example in trials with continuous out-
comes, where the aim is to test that the outcome of
n1 individuals in experimental treatment E1 is on av-
erage smaller (here smaller means better, e.g. blood
pressure) than that of n0 individuals in control group
(C), the null hypothesis H10 : µ1 ≥ µ0 is tested against
the (one-sided) alternative hypothesis H11 : µ1 < µ0.
In this case, the Type I error rate is a predefined value
α1 = Φ(zα1) where Φ(.) is the normal probability dis-
tribution function. Denote Z1 the standardised test
statistics for E1 versus control. Under H0, the distribu-
tion of the Z test statistics is standard normal, N(0, 1).
Table 1 presents the test statistics for continuous, bi-
nary, and survival outcomes with the corresponding
Fisher’s (observed) information.
If a different experimental arm E2 is compared with
the control treatment C in another independent trial,
the corresponding null hypothesis is H20 : µ2 ≥ µ0 with
the Type I error rate being similarly defined as α2. Ma-
girr et al. [11] showed that the FWER is maximised
under the global null hypothesis, HG0 , that is, when
the mean outcome in each of the experimental arms is
equal to that of the control arm, HG0 : θ
0
1 = θ
0
2 = 0.
In the above scenario, since the two trials are inde-
pendent, the overall Type I error rate (FWER) of the
two comparisons, k = 1, 2, can be calculated using the
Sˇida´k formula [12]
FWERS = Pr(reject at least one H
k
0 |HG0 )
= Pr(reject H10 or H
2
0 |HG0 )
= 1− Pr(accept H10 and H20 |HG0 )
= 1− (1− α1)(1− α2).
When α1 = α2 = α,
FWERS = 1− (1− α)2 (1)
where subscript S stands for Sˇida´k. If the control arm
observations are shared between the two pairwise com-
parisons, one can replace the term (1 − α)2 in eqn.
(1) to allow for the correlation between the two test
statistics Z1 and Z2, i.e. the correlation induced by the
shared control arm information. Dunnett [8] provided
an analytical formula to estimate the FWER when
all the comparisons start and conclude at the same
time, i.e. when all control arm observations overlap
between different comparisons. In the above scenario,
the FWER can be calculated using
FWERD = 1− Φ2(z1−α1 , z1−α2 ; ρ12) (2)
where Φ2(.; ρ12) is the standard bivariate normal prob-
ability distribution function and ρ12 is the correla-
tion between Z1 and Z2 at the final analysis. With
equal allocation ratio A = A1 = A2 across all exper-
imental arms, ρ12 =
A
A+1 [8] - e.g. ρ12 = 0.5 when
n0 = n1 = n2.
The formula for ρ12 can be extended for the sce-
nario when E2 is started later than E1 and C overlaps
with both of them, i.e. when only some of the control
arm observations are shared between the two compar-
isons. This scenario is quite common in platform trials
where new experimental arms can be added to the pre-
vious sets of pairwise comparisons, and recruitment to
the new experimental and control arms continues until
the planned end of that comparison. To achieve this,
we make use of the asymptotic properties of the effi-
cient score statistic and the Z test statistic. It has been
shown that over time the sequence of Z test statistics
approximately has an independent and normally dis-
tributed increment structure for the estimators of the
treatment effects presented in Table 1 [10] [13]. This
means that at information time t′ > t,√
N(t′)Z(t′) =
√
N(t)Z(t)+
√
N(t′)−N(t)Z(t′−t)
where N(t′) and N(t) are the total sample sizes at in-
formation times t′and t. With equal allocation ratio to
both experimental arms, if n0,12 control arm observa-
tions (where 0 < n0,12 < n0) are shared between the
two comparisons, the correlation between Z1 and Z2
can be calculated using eqn. (3) - see the online doc-
ument Supplementary Material for analytical deriva-
tions and more complex formula for the case of unequal
allocation ratio between comparisons.
ρ∗12 =
A
A+ 1
.
n0,12
n0
(3)
Note that the factor
n0,12
n0
is bounded by [0, 1] with
the upper bound equal to 1 when n0,12 = n0 (i.e.
when the two comparisons start and finish at the same
time), and the lower bound equal to 0 when there is no
shared observation in the control arm - in which case,
FWERD converges to FWERS .
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Table 1: Treatment effects, test statistics, expected information, and correlation between the test statistics of
pairwise comparisons in trials with continuous, binary, and survival outcomes, with common allocation ratio
(A).
Outcome Treatment effect Test statistics Fisher’s information (V ) Corr. between two comparisons
(θ) (Z) Complete ovlp. Partial ovlp.
(ρ12) (ρ∗12)
Continuous θc = µ1 − µ0 Z1 = θc
√
Vc Vc = (
σ20
n0
+
σ21
An0
)−1 A
A+1
A
A+1
.
n0,12
n0
θb1 = p1 − p0 Z1 = θb1
√
Vb1 Vb1 = (
p0(1−p0)
n0
+
p1(1−p1)
An0
)−1 A
A+1
A
A+1
.
n0,12
n0
Binary θb2 = log
{
p1(1−p0)
p0(1−p1)
}
Z1 = θb2
√
Vb2 Vb2 = (
1
n0p0(1−p0) +
1
An0p1(1−p1) )
−1 A
A+1
A
A+1
.
n0,12
n0
θb3 = log
{
p1
p0
}
Z1 = θb3
√
Vb3 Vb3 = (
1−p0
n0p0
+ 1−p1
An0p1
)−1 A
A+1
A
A+1
.
n0,12
n0
Survival θs = log(HR) Z1 = θs
√
Vs Vs = (d
A
(1+A)2
)−1 A
A+1
A
A+1
.
e0,12
e0
ρ12: correlation when there is complete overlap between pairwise comparisons.
ρ∗12: correlation when only n0,12(e0,12) control arm observation(events) overlap between comparisons 1 and 2.
n0,12(e0,12), shared observations(events) in control arm; n0(e0), total observations(events) in control arm; d, all events
Our analytical derivation shows that eqn. (3) ap-
plies to both continuous and binary outcome measures.
However, in survival outcomes the ratio
n0,12
n0
should
be replaced with the ratio of the shared events in the
control arm, i.e.
e0,12
e0
- see Supplementary Material for
analytical derivations and also the more complicated
formula for unequal allocation ratio. Table 1 shows the
corresponding formula for ρ∗12 by the type of outcome
measure.
3.2 Power when adding a new arm
The power of a clinical trial is the probability that
under a particular target treatment effect θ1, a truly
effective treatment is identified at the final analysis.
In multi-arm designs, per-pair (pairwise) power (ω)
[14] calculates this probability for a given experimen-
tal arm against the control. In multi-arm settings, how-
ever, there are other definitions of power that might be
of interest - depending on the objective of the trial. In
the above setting where there are two comparisons, de-
fine the target treatment effects under the alternative
hypothesis for each of the comparisons as θ11 and θ
1
2,
respectively. Disjunctive (any-pair) power is the prob-
ability of showing a statistically significant effect under
the targeted effects for at least one comparison:
Ωd = Pr(reject at least one H
k
0 |θ1 = θ11,θ2 = θ12)
= 1− Pr(accept H10 and H20 |θ1 = θ11,θ2 = θ12)
When the two comparisons, k = 1, 2, are independent,
i.e. ρ12 = 0, disjunctive power (Ωd) is defined as
Ωd = 1− (1− ω1)(1− ω2). (4)
If ρ12 6= 0, then Ωd is calculated using
Ωd = 1− Φ2(z1−ω1 , z1−ω2 ; ρ12) (5)
Conjunctive (all-pairs) power is the probability of
showing a statistically significant effect under the tar-
geted effects for all comparison pairs. When the two
tests are independent, conjunctive power (Ωc) is
Ωc = Pr(reject all H
k
0 |θ1 = θ11,θ2 = θ12)
= Pr(reject H10 and H
2
0 |θ1 = θ11,θ2 = θ12)
= ω1.ω2
Given the correlation ρ12, then Ωc is calculated using
Ωc = Φ2(zω1 , zω2 ; ρ12) (6)
If a new experimental arm is added later on, the cor-
responding formula for ρ∗12 in Table 1 can be used to
calculate both disjunctive (Ωd) and conjunctive (Ωc)
powers in this scenario.
4 Results
In this section, we first show the results of our simula-
tions to explore the validity of eqn. (3) to estimate ρ∗12,
and to study the impact of the timing of the addition
of a new experimental arm on the FWER and different
types of power. Because of the censoring, survival out-
comes are generally considered the most complex type
of outcomes listed in Table 1. We conduct our simula-
tions in this setting. Then, we estimate the correlation
structure between the test statistics of different com-
parisons in the STAMPEDE trial, including the first
three of the added arms to the original set of com-
parisons. Finally, to illustrate the design implications
in planned scenarios, we show an application in the
design of the RAMPART trial.
4.1 Simulation design
In our simulations, we considered a hypothetical three-
arm trial with one control, C, and two experimental
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Table 2: Three different trial designs for each pairwise
comparison of experimental arm versus control in a
3-arm trial.
Scenario A e0 n0 Overall trial period
1 0.5 401 788 2.33
2 1 264 545 2.18
3 2 196 389 2.36
Key: A, allocation ratio; e0, total control arm events required;
n0, number of patients accrued to control arm by the end of trial;
Overall trial period, duration (in time units) up to the final analysis.
arms (E1 and E2). We applied similar design parame-
ters to those in [14] - see Section 2.7.1 - taking median
survival for the time-to-event outcome of 1 yr (hazard
λ1 = 0.693 in control arm). We generated individual
time-to-event patient data from an exponential distri-
bution and estimated the correlation between the test
statistics of the two pairwise comparisons Z1 and Z2
when E2 was initiated at different time points after the
start of the experimental arm E1 and control. Accrual
rates were assumed to be uniform throughout (across
the platform) and set to 500 patients per unit time for
both comparisons.
As in the STAMPEDE trial, the comparison set of
patients for the deferred experimental arm E2 are the
contemporaneously-recruited control arm C individu-
als. This means that in our simulations recruitment to
the control arm continued until conclusion of that re-
quired for the E2 comparison. As for the final stage of
STAMPEDE, the design significance level and power
were chosen as αi = 0.025 and ωi = 0.9, i = 1, 2 in
all scenarios. The target hazard ratio under the alter-
native hypothesis in both pairwise comparisons were
0.75. To investigate the FWER under different alloca-
tion ratios, we carried out our simulations under three
allocation ratios of A = {0.5, 1, 2}. Table 2 [Table 2
NEAR HERE] presents details of the design param-
eters, including trial timelines, in each pairwise com-
parison for different values of A. Calculations for Table
2 were done in Stata using the nstage program [15].
In simulations, 50, 000 replications were generated in
each scenario.
Finally, the main aim of our simulation study is to
explore the impact of the timing of adding a new ex-
perimental arm on the correlation structure and the
value of the FWER. For this reason, only one original
comparison was included in our simulations. In Section
5 and Discussion, we discuss how the FWER can be
strongly controlled, and address other relevant design
issues, when more pairwise comparisons start at the
begining.
4.2 Simulation results
The results are summarised in Table 3. The table
shows the estimates of the correlation between the
test-statistics of the two pairwise comparisons as com-
puted from the corresponding equation for ρ∗12 in Table
1, by the timing of when the second experimental arm
E2 was added. We estimated the number of shared
control arm events, e
0,12
, via simulation. For each sce-
nario, we also simulated individual patient data under
the null hypothesis and computed both test statistics,
which were then used to estimate the correlation be-
tween them. The results are also included in Table 3,
i.e. ρ̂∗12. The results indicate that the estimated values
of ρ̂∗12 accord well with the corresponding values ob-
tained from the formula in all experimental conditions
- they only differed in the third decimal place.
The results for each allocation ratio indicate that
when E2 starts later than E1 and C, the estimates
of the FWER and ρ̂∗12 are driven by the shared con-
trol arm events between the two pairwise comparisons
- see Table 3. The higher the number of the shared
control arm events, the lower the value of the FWER
is because ρ∗12 is higher. The FWER reaches its maxi-
mum when there is no shared information between the
two pairwise comparisons at which point eqn. (1) can
be used to calculate the FWER. This is when the two
pairwise comparisons are effectively two completely in-
dependent trials in one protocol. In this case, Bonfer-
roni correction can also provide a good approximation,
i.e. α1 + α2 = 0.05.The results indicate that, even for
a correlation of as high as 0.30, the Bonferroni correc-
tion provides a good approximation. This correlation
threshold corresponds to an overlap (in terms of ‘infor-
mation time’) of about 60% between the newly added
comparison and that of the existing one for an equal
allocation ratio (A = 1). If more individuals are al-
located to the control arm (i.e. A < 1), the amount
of overlap has to be even higher to achieve this cor-
relation threshold, e.g. about 87% when A < 1 in our
simulations for either experimental arm.
Furthermore, it is evident from our simulations that
when more individuals are allocated to the control arm
(i.e. A < 1), the timing of adding a new experimental
arm has very little impact on the value of the FWER.
For an equal allocation ratio (A = 1) the impact on
the FWER is modest; whereas for the uncommon sce-
nario of allocation ratio A > 1, the impact is moderate.
Therefore, in many multi-arm trials, where often more
individuals are allocated to the control arm than each
experimental arm, the timing of the addition of a new
experimental arm is unlikely to be a major issue.
Finally, Table 4 presents the disjunctive and conjunc-
tive powers in each scenario. The results indicate that
the timing of the addition of the new arm has more im-
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Table 3: Estimates of the correlation between the test-statistics of the two pairwise comparisons, Z1 and Z2,
by the timing of the addition of experimental arm E2. The values for ρ
∗
12 are calculated from eqn. (3). The
estimates ρ̂∗12 are obtained from simulating individual patient data. The number of trial-level replicates is 50,000
in all experimental conditions.
Allocation Ratio = 0.5 Allocation Ratio = 1 Allocation Ratio = 2
Time E2 Shared ctrl. Shared ctrl. Shared ctrl.
started arm events ρ∗12 ρ̂
∗
12 FWER arm events ρ
∗
12 ρ̂
∗
12 FWER arm events ρ
∗
12 ρ̂
∗
12 FWER
0.0 401 0.33 0.33 0.047 264 0.50 0.50 0.045 196 0.66 0.66 0.043
0.2 349 0.29 0.29 0.048 226 0.43 0.43 0.046 170 0.57 0.57 0.044
0.4 298 0.25 0.25 0.048 190 0.36 0.36 0.047 144 0.49 0.49 0.045
0.6 249 0.20 0.20 0.048 155 0.29 0.29 0.048 121 0.41 0.41 0.046
0.8 204 0.17 0.18 0.049 123 0.23 0.23 0.048 98 0.33 0.33 0.047
1.0 161 0.13 0.14 0.049 94 0.18 0.18 0.049 77 0.26 0.26 0.048
1.2 122 0.10 0.10 0.049 68 0.13 0.13 0.049 57 0.19 0.19 0.049
1.4 88 0.07 0.07 0.049 45 0.09 0.09 0.049 41 0.14 0.14 0.049
1.6 57 0.05 0.05 0.049 26 0.05 0.05 0.049 26 0.09 0.09 0.049
1.8 33 0.03 0.03 0.049 12 0.02 0.02 0.049 15 0.05 0.05 0.049
2.0 14 0.01 0.02 0.050 3 0.00 0.00 0.050 6 0.02 0.02 0.049
Table 4: Disjunctive (Ωd) and conjunctive (Ωc) powers by the timing of the addition of the second arm and the
correlation between the test statistics of the two pairwise comparisons.
Allocation Ratio = 0.5 Allocation Ratio = 1 Allocation Ratio = 2
Time E2
started ρ∗12 Ωd Ωc ρ
∗
12 Ωd Ωc ρ
∗
12 Ωd Ωc
0.0 0.33 0.977 0.823 0.50 0.968 0.833 0.66 0.956 0.844
0.2 0.29 0.979 0.821 0.43 0.972 0.828 0.57 0.963 0.837
0.4 0.25 0.980 0.819 0.36 0.975 0.825 0.49 0.968 0.832
0.6 0.20 0.983 0.817 0.29 0.979 0.821 0.41 0.972 0.827
0.8 0.17 0.984 0.816 0.23 0.982 0.819 0.33 0.977 0.823
1.0 0.13 0.986 0.815 0.18 0.984 0.817 0.26 0.980 0.820
1.2 0.10 0.987 0.813 0.13 0.986 0.815 0.19 0.983 0.817
1.4 0.07 0.988 0.812 0.09 0.987 0.813 0.14 0.985 0.815
1.6 0.05 0.988 0.812 0.05 0.988 0.812 0.09 0.987 0.813
1.8 0.03 0.989 0.811 0.02 0.989 0.810 0.05 0.988 0.812
2.0 0.01 0.990 0.810 0.00 0.990 0.810 0.02 0.989 0.810
pact on both types of powers. Nonetheless, the impact
is still relatively low - particularly, when the allocation
ratio is less than one. However, the degree of overlap
affects the two types of powers in opposite directions.
While conjunctive power decreases with smaller over-
lap, disjunctive power increases in such scenario.
4.3 FWER of STAMPEDE when new arms were added
In this section, we calculate the correlation between
the test statistics of different pairwise comparisons in
STAMPEDE when new arms are added. The newly
added therapies look to address different research ques-
tions than those of the original comparisons. When
the first new arm was added, STAMPEDE had only
3 experimental arms open to accrual because arms E3
and E5 were stopped at their second interim look. The
new experimental arms E6, E7, and E8 were added in
November 2011, January 2013, and July 2014, respec-
tively. The final stage design parameters of the three
added comparisons were similar to those of the orig-
inal comparisons (i.e. final stage sig. level and power
of αi = 0.025 and ωi = 0.90), except that their allo-
cation ratio was set as A6 = A7 = A8 = 1. Some of
the control arm patients recruited from the start of E6
and E7 are shared between the original family and the
new comparisons - see the top section of Figure 1. In all
three added comparisons the final analysis takes place
when 267 primary outcome events are observed in the
contemporaneously-randomised control arm patients.
To calculate the correlation between different test
statistics, we needed to estimate (or predict) the
shared control arm events of the corresponding pair-
wise comparisons - Supplementary Material explains
this in detail. Only 7 common control arm primary
outcome events were expected to be shared between
E7 and the original family of pairwise comparisons
at their respective primary analysis (see Table 1 in
Supplementary Material). For the E6 comparison, the
(expected) number of common control arm primary
outcome events is 77, but it is still a small fraction
of the total events required at its main analysis. As a
result, the correlations between the corresponding test
statistics are quite low in both cases, i.e. ρ̂∗k6 = 0.12
and ρ̂∗k7 = 0.01, k = 1, 2, 4. Between E6 and E7 com-
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parisons, the number of shared primary events were
expected to be higher (e0,12 = 92) which will result
in a slightly higher correlation. But, even in this case
the correlation is well below 0.30. Not only do the
first three added comparisons pose distinct research
questions, the correlation between the test statistics of
the corresponding pairwise comparisons are very low.
If the strong control of the FWER was required for
the three added arms, the simple Bonferroni correc-
tion could have been used to approximate Dunnett’s
correction since both the correlation and the amount
of overlap between the three comparisons are very low.
4.4 Design application: RAMPART trial
Renal Adjuvant MultiPle Arm Randomised Trial
(RAMPART) is an international phase III trial of ad-
juvant therapy in patients with resected primary renal
cell carcinoma (RCC) at high or intermediate risk of
relapse. In this multi-arm multi-stage (MAMS) trial,
the control arm (C), i.e. active monitoring, and first
two experimental arms (E1 and E2) are due to start
recruitment at the same time, with another experi-
mental treatment (E3) - which is in early phase devel-
opment - expected to be added at least two years after
the start of the first three arms. The deferred exper-
imental arm, E3, will share some of the control arm
patients with the other two comparisons and only be
compared against those recruited contemporaneously
to the control arm over the same period. No head-to-
head comparison of the experimental arms planned,
and all the stopping boundaries are prespecified. The
trial design has passed both scientific and regulatory
reviews, obtained approval from both the EMA and
FDA, and started in mid-2018. Upon reviews of the
design, it was deemed necessary to control the FWER
at 2.5% (one-sided) in this trial, whether or not the
deferred arm is added. Table 2 in Supplementary Ma-
terial presents the design details for RAMPART - for
full details of the design and trial protocol, please see
https://www.rampart-trial.org/.
We carried out simulations to investigate the impact
of the timing of adding the third experimental arm on
the FWER. This was done at 2 years, 3 years and 4
years into the two original comparisons. The simula-
tion results confirmed our findings that the timing of
the addition of E3 has no practical impact on the value
of FWER. Therefore, the overall (one-sided) Type I er-
ror rate was proportionally split between the two com-
parisons that start at the same time and the deferred
comparison, i.e. E3 vs. C, using the Dunnett correc-
tion. Note that in the two comparisons that start at the
same time there is a large proportion of shared control
arm information. To make use of the induced correla-
tion between the test statistics of these comparisons,
simulations were used to approximate Dunnett prob-
ability in this case. Simulations showed that the final
stage significance level of 0.0097 in all pairwise com-
parisons controls the overall FWER at 2.5% when the
deferred arm is added later on. Our simulations also
showed that the final stage significance level of the two
original pairwise comparisons can be increased to 0.015
if E3 is not added to buy back the unspent Type I er-
ror of the third pairwise comparison. This will decrease
the required sample size in these two comparisons - see
the last two columns of Table 2 in Supplementary Ma-
terial - and will bring forward the (expected) timing of
the final analysis in both E1 vs. C comparison (∼ 10
months) and in E2 vs. C comparison (∼ 4 months).
5 Strong control of FWER when required
Opinions differ as to whether the FWER needs to be
strongly controlled in all multi-arm trials [9] [6] [16]
[17] [18] [19]. In our view there are cases such as exam-
ining different doses of the same drug where the con-
trol of the FWER might be necessary to avoid offering
a particular therapy an unfair advantage of showing
a beneficial effect. However, in many multi-arm tri-
als where the research treatments in the existing and
added comparisons are quite different from each other,
we believe that the greater focus should be on control-
ling each pairwise error rate [20] [9]. To support this
view consider the following: if two distinct experimen-
tal treatments are compared to a current standard in
independent trials, it is accepted that there is no re-
quirement for multiple testing adjustment [16]. There-
fore, it seems fallacious to impose an unfair penalty if
these two hypotheses are instead assessed within the
same protocol where both hypotheses are powered sep-
arately and appropriately. This is seen most clearly
when the data remain entirely independent, for exam-
ple, when these are non-overlapping with effectively
separate control groups.
Our results indicate that the timing of adding a
new experimental arm to an ongoing multi-arm trial -
where the allocation ratio is often one or less, i.e. more
patients are recruited to the control arm - is almost ir-
relevant in terms of changing the value of the FWER.
Even in cases where there is an overlap (in terms of ‘in-
formation time’) of 60% the impact on the increase of
FWER can be negligible. The practical implication of
this finding is that in cases where strong control of the
FWER is required, one can simply divide the overall
FWER by the total number of pairwise comparisons
K, including the added arms, and take the worse case
scenario of complete independence and design the de-
ferred arm with αK as an independent trial. In this
case, they can be considered as separate trials and the
new hypothesis can be powered separately and appro-
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When adding a new experimental arm, 
is strong control of the FWER required?
Control PWER
Power each arm 
separately
Allocation ratio(1) < 1
and/or
Limited overlap(2)
and/or
Correlation(3) ≤ 0.30
Divide the overall FWER 
by 𝐾(4), and allocate  𝛼𝐾
for the added arm
Power the added arm 
with 𝛼𝐾 separately,
power the other arms 
using eqn. (2) with the 
remaining overall alpha 
Use eqn. (2) with 
correlation 𝜌∗ to control 
FWER 
YesNo
Yes No
Figure 2: Strategies to control Type I error rate when adding new experimental arms.
Key: 1) allocation ratio for either of the new or ongoing comparisons; 2) e.g. < 60% of information time when
A = 1; 3) correlation between the test statistics of pairwise comparisons; 4) K is the total number of pairwise
comparisons, including the added arms.
priately. If the FWER for the protocol as a whole is
required to be controlled at a certain level, as in the
RAMPART trial, then the overall Type I error can be
split accordingly between the original and added com-
parisons. This seems to be a practical strategy to con-
trol the FWER because in most cases the exact timing
of the availability of a new experimental therapy may
not be determined in advance. If the new experimen-
tal arm is not actually added, the final stage signifi-
cant level of the original comparisons can be relaxed
to achieve the target FWER. There might be situa-
tions where more experimental therapies are available
later than planned at the design stage. In this case, one
way to control the FWER for the new set of pairwise
comparisons is to reduce the final significance level for
the existing comparisons. But, this would increase the
(effective) sample size of the existing comparisons and
thus the overlap between the new and existing com-
parisons would increase - which in turn would affect
FWER. In this case, a recursive procedure would be
required to achieve the desired level for the FWER.
Finally, we emphasise that the decision to control the
PWER or the FWER (for a set of pairwise compar-
isons) depends on the type of research questions being
posed and whether they are related in some way, e.g.
testing different doses or duration of the same therapy
in which case the control of the FWER may be re-
quired. These are mainly practical considerations and
should be determined on a case-by-case basis in the
light of the rationale for the hypothesis being tested
and the aims of the protocol for the trial. Once a de-
cision has been made to strongly control (or not) the
FWER, Figure 2 summarises our guidelines on how
to power the added comparison to guarantee strong
control of the FWER. We believe this is a logical and
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coherent way to assess the control of Type I error in
most scenarios.
6 Discussion
It is practically advantageous to add new experimental
arms to an existing trial since it not only prevents the
often lengthy process of initiating a new trial but also
it helps to avoid competing trials being conducted [1]
[2]. It also speeds up the evaluation of newly emerging
therapies, and can reduce costs and numbers of pa-
tients required [3] [4]. In this article, we studied the
familywise type I error rate and power when new ex-
perimental arms are added to an ongoing trial.
Our results show that, under the design conditions,
the correlation between the test statistics of pairwise
comparisons is affected by the allocation ratio and the
number of common control arm shared observations in
continuous and binary outcomes and primary outcome
events in trials with survival outcomes. The correlation
decreases if more individuals are proportionately allo-
cated to the control arm. This correlation increases as
the proportion of shared control arm information in-
creases, and it reaches its maximum when the number
of observations (in continuous and binary outcomes)
or events (in survival outcomes) is the same in both
pairwise comparisons. Our results also showed that the
correlation between the pairwise test statistics and the
FWER are inversely related. The higher the correla-
tion, the lower the FWER is.
We reiterate that in a platform protocol the emphasis
of the design should be on the control of the PWER
if distinct research questions are posed in each pair-
wise comparison, particularly when there is little or
no overlap between the comparisons. To support this
we would argue that the scientific community at large
is increasingly judging the effects of treatments using
meta-analysis rather than focusing on specific individ-
ual trial results [21]. For this purpose, the readers and
reviewers are not concerned about the value of Type I
error for each trial or a set of such trials.
Another relevant question in a multi-arm platform
protocol is what constitutes a family of pairwise com-
parisons. The difficulty in specifying a family arises
mainly due to the dynamic nature of a platform trial,
i.e. stopping of accrual to experimental treatments for
lack-of-benefit, and/or adding new treatments to be
tested during the course of the trial. The definition of
a family in this context involves a subtle balancing of
both practical and statistical considerations. The prac-
tical and non-statistical considerations can be more
complex in nature, hence the need for (case-by-case)
assessment. Moreover, therapies that emerge over time
are more likely to be distinct rather than related, for
example, different drugs entirely rather than doses of
the same therapy. For this reason, each hypothesis is
more likely to inform a different claim of effectiveness
of previously tested agents. An example is the STAM-
PEDE platform trial where distinct hypotheses were
being tested in each of the new experimental arms,
and these do not contribute towards the same claim of
effectiveness for an individual drug. In this case, the
chance of a false positive outcome for either claim of
effectiveness is not increased by the presence of the
other hypothesis.
Although we have focused on single stage designs,
our approach can easily be extended to the multi-stage
setting where the stopping boundaries are prespecified.
As we have shown in RAMPART, if there are interim
stages in each pairwise comparison, the correlation be-
tween the test statistics of different pairwise compar-
isons at interim stages also contribute to the overall
correlation structure. Similar correlations formula to
those presented in Table 1 can be analytically driven,
see Supplementary Material, to calculate the interim
stages correlation structure. Our experience has shown
that even in this case the correlation between the final
stage test statistics principally drives the FWER. Our
empirical investigation has indicated that even large
changes in the correlation between the interim stage
test statistics have minimal impact on the estimates
of the FWER. However, if researchers wish to have
the flexibility of non-binding stopping guidelines, then
the correlation structure can be estimated in the same
manner as discussed in this article by considering the
correlation between the final stage test statistics only.
Furthermore, in our simulations one experimental
arm started with control at the begining of the trial
since the aim was to investigate the impact of the tim-
ing of adding new experimental arms on the correla-
tion structure and the value of the FWER. In many
scenarios such as RAMPART and STAMPEDE, more
than one experimental arms start at the same time in
which case there will be substantial overlap in infor-
mation between the pairwise comparison of these arms
to control. If strong control of the FWER is required
in this case, Dunnett’s correction (i.e. eqn. (2)) should
be used to calculate the proportion of the Type I error
rate that is allocated to each of these comparisons as
we have done in the case of RAMPART.
Moreover, in some designs such as RAMPART it is
required to control the FWER at a pre-specified level.
In general, any unplanned adaptation would affect the
FWER of a trial. This includes the unplanned addi-
tion of a new experimental arm. It will be possible to
(strongly) control the FWER if the addition of new
pairwise comparisons is planned at the design stage of
a MAMS trial as we have shown in the RAMPART ex-
ample. In this case, the introduction of a new hypoth-
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esis will be completely independent of the results of
the existing treatments. In platform protocols in gen-
eral, it becomes infeasible to control the FWER for all
pairwise comparisons as new experimental treatments
are added to the existing sets of pairwise comparisons.
In this article, we have investigated one statistical
aspect of adding new experimental arms to a platform
trial. The operational and trial conduct aspects also
require careful consideration, some of which have al-
ready been addressed in [1]. Sydes et al. [1] put for-
ward a number of useful criteria that can be thought
about when considering the rationale for adding any
new experimental arm. Both statistical and conduct
aspects require careful examination to efficiently de-
termine whether and when new experimental arms can
be added to an existing platform trial.
6.1 Conclusions
The familywise type I error rate is mainly driven by the
number of pairwise comparisons and the corresponding
pairwise Type I errors rates. The timing of adding a
new experimental arm to an existing platform protocol
can have minimal, if any, impact on the FWER. The
simple Bonferroni or Sˇida´k correction can be used to
approximate Dunnett’s correction in eqn. (2) if there is
not a substantial overlap between the new comparison
and those of the existing ones, or when the correlation
between the test statistics of the new comparison and
those of the existing comparisons is small, less than,
say, 0.30.
Author details
1MRC Clinical Trials Unit at UCL, Insttitute of Clinical Trials and
Methodology, 90 High Holborn, WC1V 6LJ, London, UK. 2Clinical
Statistics, GlaxoSmithKline, Stockley Park, Middlesex, UK. 3Department
of Health Services Research and Policy, LSHTM, London, UK.
References
1. Sydes MR, Parmar MK, Mason MD, Clarke NW, Amos C, Anderson J,
et al. Flexible trial design in practice - stopping arms for lack-of-benefit
and adding research arms mid-trial in STAMPEDE: a multi-arm
multi-stage randomized controlled trial. Trials. 2012;13(1):168.
2. Elm JJ, Palesch YY, Koch GG, Hinson V, Ravina B, Zhao W. Flexible
analytical methods for adding a treatment arm mid-study to an
ongoing clinical trial. Journal of Biopharmaceutical Statistics.
2012;22:758–772.
3. Cohen DR, Todd S, Gregory WM, Brown JM. Adding a treatment arm
to an ongoing clinical trial: a review of methodology and practice.
Trials. 2015;16:179.
4. Ventz S, Alexander BM, Parmigiani G, Gelber RD, Trippa L. Designing
Clinical Trials That Accept New Arms: An Example in Metastatic
Breast Cancer. Journal of Clinical Oncology. 0;0(0):JCO.2016.70.1169.
5. Sydes MR, Parmar MK, James ND, Clarke NW, Dearnaley DP, Mason
MD, et al. Issues in applying multi-arm multi-stage methodology to a
clinical trial in prostate cancer: the MRC STAMPEDE trial. Trials.
2009;10:39.
6. Wason JMS, Stecher L, Mander AP. Correcting for multiple-testing in
multi-arm trials: is it necessary and is it done? Trials. 2014;15:364.
7. Bratton DJ, Parmar MKB, Phillips PPJ, Choodari-Oskooei B. Type I
error rates of multi-arm multi-stage clinical trials: strong control and
impact of intermediate outcomes. Trials. 2016;17:309.
8. Dunnett CW. A Multiple Comparison Procedure for Comparing
Several Treatments with a Control. Journal of the American Statistical
Association. 1955;50(272):1096–1121.
9. Cook RJ, Farewell VT. Multiplicity Considerations in the Design and
Analysis of Clinical Trials. Journal of the Royal Statistical Society
Series A (Statistics in Society). 1996;159:93–110.
10. Follmann DA, Proschan MA, Geller NL. Monitoring Pairwise
Comparisons in Multi-Armed Clinical Trials. Biometrics.
1994;50(2):325–336.
11. Magirr D, Jaki T, Whitehead J. A generalized Dunnett test for
multi-arm multi-stage clinical studies with treatment selection.
Biometrika. 2012;99(2):494–501.
12. Sidak Z. Rectangular Confidence Regions for the Means of
Multivariate Normal Distributions. Journal of the American Statistical
Association. 1967;62(318):626–633.
13. Tsiatis AA. The asymptotic joint distribution of the efficient scores
test for the proportional hazards model calculated over time.
Biometrika. 1981;68:311–315.
14. Royston P, Barthel FM, Parmar MK, Choodari-Oskooei B, Isham V.
Designs for clinical trials with time-to-event outcomes based on
stopping guidelines for lack of benefit. Trials. 2011;12:81.
15. Bratton DJ, Choodari-Oskooei B, Royston P. A menu-driven facility
for sample size calculation in multi-arm multi-stage randomised
controlled trials with time-to-event outcomes: Update. Stata Journal.
2015;15(2):350–368.
16. Howard DR, Brown JM, Todd S, Gregory WM. Recommendations on
multiple testing adjustment in multi-arm trials with a shared control
group. Statistical Methods in Medical Research. 2016;p. Early/online
view.
17. Proschan MA, Waclawiw MA. Practical Guidelines for Multiplicity
Adjustment in Clinical Trials. Controlled Clinical Trials.
2000;21:527–539.
18. Rothman KJ. No Adjustments Are Needed for Multiple Comparisons.
Epidemiology. 1990;1:43–46.
19. Freidlin B, Korn EL, Gray R, Martin A. Multi-arm clinical trials of new
agents: some design considerations. Clin Cancer Res.
2008;14(14):4368–71.
20. O’Brien PC. The Appropriateness of Analysis of Variance and
Multiple-Comparison Procedures. Biometrics. 1983;39(3):787–788.
21. Vale CL, Burdett S, Rydzewska LHM, Albiges L, Clarke NW, Fisher D,
et al. Addition of docetaxel or bisphosphonates to standard of care in
men with localised or metastatic, hormone-sensitive prostate cancer: a
systematic review and meta-analyses of aggregate data. Lancet
Oncology. 2015;17(2):243–256.
